Life Sciences Café

Start:
30 September 2010
Location:
De Stal, Leiden, the Netherlands
Contact:
Miranda de Regt

In collaboration with Mibiton, we invite you to attend the meeting on the succesful collaboration between the Leiden Biosciences companies Prosensa Therapeutics and Proxy Laboratories.

During the presentations, the novel infrastructure to develop novel medicines towards Duchenne muscular dystrophy disease will be highlighted. The collaborating companies will also elaborate on the role of the infrastructure fund 'Mibiton Share', which is supported by the ministry of Economic Affairs.

Programme:

16.30 hours
Welcome

17.00 hours
Opening and explanation Mibiton Share by Bart Bergstein, Vice Chairman Mibiton

17.10 hours
Movie: Introduction to the Duchenne muscular dystrophy followed by presentation:
'Mass spectrometry as a highly qualified tool to analyse novel drug candidates for Duchenne muscular dystrophy' by Brigitte Wanner-Burm PhD, manager of the QC and Analytical Development Division of Prosensa Therapeutics BV

17.20 hours
Presentation: 'Access to GxP cerfitied facilities for biotech start-ups' by Ruud Santing, managing director Proxy Laboratories

17.25 hours
Presentation by Professor G.J.B. van Ommen, LUMC Division of Human Genetics

17.30 hours
Closing remarks by Bart Bergstein, vice president Mibiton

17.35 hours
Drinks and networking opportunity

19.00 hours
Close

If you would like to attend the Life Sciences Café, registration is needed! Please send an e-mail with your company details and name to miranda.de.regt@leidenbiosciencepark.nl to register your attendance.

To attend our Life Sciences Cafés on a regular basis, it is necessary to become a member. Membership costs € 100 (ex. VAT) per year for company representatives and € 50 (ex. VAT) for members from knowledge institutions.

 For more information about our membership please send an e-mail to info@leidenbiosciencepark.nl. You will receive an application form and the general conditions by return.